Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

The process of searching for a new job and going through assessment centres can be a nervy and stressful time.
Arfan, 2015

Cephalon highlights positive data from large-scale Nuvigil trial

11 May 2011 00:00 in Pharmaceutical Company Product News

Cephalon has published new clinical trial data that demonstrates the benefits its drug Nuvigil can offer to sufferers of excessive sleepiness associated with shift work disorder.

The treatment has been analysed among 383 patients in a six-week placebo-controlled phase IV study, which was the largest shift work disorder trial of its kind ever conducted.

It was found that Nuvigil was able to improve subjects' overall clinical condition late in their shifts, including during the commute home, while patients using the Cephalon drug also scored higher on the Global Assessment of Functioning scale.

Dr Milton Erman, the study's lead investigator and a clinical professor of psychiatry at the University of California San Diego, said this shows the drug's importance for those with unconventional working hours.

"This study reinforces the need for healthcare professionals to learn more about this disorder and about how treatment options like Nuvigil may be of help," he added.

Earlier this month, Cephalon posted strong financial results for the first quarter of 2011, while also announcing the agreement of a deal that will see the company acquired by Teva.ADNFCR-8000103-ID-800527235-ADNFCR

Other news stories from 11/05/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd